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Bacterial virulence mechanisms are attractive
targets for antibiotic development because they are
required for the pathogenesis of numerous global in-
fectious disease agents. The bacterial secretion sys-
tems used to assemble the surface structures that
promote adherence and deliver protein virulence
effectors to host cells could comprise one such ther-
apeutic target. In this study, we developed and per-
formed a high-throughput screen of small molecule
libraries and identified one compound, a 2-imino-5-
arylidene thiazolidinone that blocked secretion and
virulence functions of a wide array of animal and
plant Gram-negative bacterial pathogens. This com-
pound inhibited type III secretion-dependent func-
tions, with the exception of flagellar motility, and
type II secretion-dependent functions, suggesting
that its target could be an outer membrane compo-
nent conserved between these two secretion sys-
tems. This work provides a proof of concept that
compoundswith a broad spectrumof activity against
Gram-negative bacterial secretion systems could be
developed to prevent and treat bacterial diseases.
INTRODUCTION
In the twentieth century the treatment of infectious diseases was
revolutionized by the development of antibiotics (Morens et al.,
2004). However, due to their widespread use, resistance to anti-
biotics is increasing on a global scale, such that adequate ther-
apies are lacking for both previously controlled and emerging
bacterial diseases (Levy and Marshall, 2004; Marra, 2006;
Morens et al., 2004). Moreover, the molecular targets and mech-
anisms of action of most newly developed antibiotics are similar
to current ones (Levy and Marshall, 2004; Nathan, 2004), reduc-
ing their efficacy in the face of resistance. The effective treatment
of infectious diseases in the face of increasing antibiotic resis-
tance will likely require the development of pharmaceuticals
that act upon previously unutilized conserved targets (Levy and
Marshall, 2004). Recently, bacterial virulence properties haveCell Hobeen proposed and explored as attractive targets for the devel-
opment of new therapeutic agents (Marra, 2006). This strategy
could decrease the likelihood for selection of resistance because
in contrast to currently available antibiotics these agents would
presumably not require inhibition of general bacterial growth.
Such compounds would likely have the advantage of sparing
commensals, reducing the likelihood of side effects. A potential
disadvantage of pathogenic mechanisms as therapeutic targets
is that many are microbial specific, necessitating more rapid
pathogen identification than currently is in clinical practice.
Gram-negativebacterial virulencesecretion systems represent
particularly appealing virulence factor targets because they are
essential for a wide array of animal and plant infectious diseases
and have some functionally conserved components. Two prom-
inent examples of Gram-negative bacterial virulence-associated
secretion systems, termed type II secretion (T2S) and type III se-
cretion (T3S), are responsible for the pathogenesis ofmany infec-
tious diseases including plague, gastroenteritis, Gram-negative
pneumonia, dysentery, enteric fever, tularemia, trachoma, endo-
metritis, and a variety of plant diseases. T2S is also known as the
terminal component of the sec-dependent or general secretory
pathway (GSP) because substrates are secreted across the bac-
terial inner membrane by the GSP and subsequently transported
across the outer membrane (Cianciotto, 2005). T2S systems
secrete a variety of mammalian toxins as well as proteins, which
degrade host cell components, including proteins, lipids, and
sugars of the extracellular matrix (Cianciotto, 2005). Interestingly,
a number of the genes required for T2S are homologous to those
required for type IV pilus (T4P) assembly on the cell surface of
some bacteria (Mattick, 2002). T4P are required for twitchingmo-
tility, a flagella-independent formof bacterial translocation,which
plays a role in host colonization and biofilm formation in organ-
isms, such as enterophathogenic E. coli (EPEC), Pseudomonas
aeruginosa, Vibrio cholera, and Nieserria gonorrhoea (Mattick,
2002). T3S systems are complex multiprotein organelles that as-
semble in thebacterialmembraneofmore than25Gram-negative
animal and plant pathogens to delivermultiple virulence proteins,
or effector proteins, directly from the bacterial cytosol into host
cells. These secreted proteins influence host cell physiology by
altering a variety of antibacterial functions with resultant disease
(Cornelis and Van Gijsegem, 2000).
In recent years whole-cell based high-throughput screens
have been performed to identify inhibitors of T3S systemsst & Microbe 4, 325–336, October 16, 2008 ª2008 Elsevier Inc. 325
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These screens have identified several classes of synthetic
compounds and the natural product glycolipid caminosides
as active for inhibition of T3S in a broad range of Gram-nega-
tive bacterial pathogens, including Yersinia, Chlamydia, and
Salmonella (Gauthier et al., 2005; Kauppi et al., 2003; Linington
et al., 2002, 2006; Negrea et al., 2007; Nordfelth et al., 2005;
Wolf et al., 2006). The salicylanilides likely inhibit T3 gene
transcription while the salicylideneacylhydrazides, sulfonylami-
nobenzanilides, and caminosides have unknown targets. In
this study, we designed and implemented a tractable high-
throughput screen (HTS) for the identification of compounds
that could function to inhibit T3S systems and found a small
molecule that broadly inhibits T3 and T2 bacterial secretion
systems.
RESULTS
A High-Throughput Screen using Engineered
S. typhimurium Identifies a 2-Imino-5-Arylidene
Thiazolidinone as an Inhibitor of T3S
To screen biological and chemical small-molecule libraries for in-
hibitors of bacterial secretion, we designed and employed
a whole-cell HTS for inhibitors of T3S. T3S systems, which are
evolutionarily related to flagella, are complex multiprotein organ-
elles that assemble in the bacterial membrane to deliver viru-
lence proteins directly from the bacterial cytosol into host cells.
A strain of S. typhimuriumwas constructed that secretes a phos-
pholipase A2 reporter construct in a T3S-dependent manner.
Specifically, this strain contains a protein fusion between the
S. typhimurium T3S substrate SipA and the Yersinia enterocoli-
tica T3 secreted substrate YplA. The first 59 amino acidswere re-
moved from YplA because they contain the signal sequence for
its secretion by Y. enterocolitica but are not required for its enzy-
matic activity (Hatic et al., 2002;Warren and Young, 2005). Phos-
pholipase activity is an efficient and well-recognized reporter in
HTassaysbecauseof theavailability of phospholipasesubstrates
with a cleavage product that is fluorescent. Our assay was
based on cleavage, by our phospholipase A2 reporter construct,
of the substratePED6:N-((6-(2,4-dinitro-phenyl)amino)-hexanoyl)-
2-(4,4-difluro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-
pentanoyl)-1-hexadecanoyl-sn-glycero-3-phosphoethanolamine
(Invitrogen, Carlsbad, CA, USA). Such cleavage results in an in-
crease in absorbance readily measured using a fluorometer.
When PED6 is added directly to a culture of the engineered
Salmonella strain, fluorescence is proportional to the amount of
phospholipase reporter secreted by the T3S system.
Using this HTS, 92,000 small molecules from both natural and
synthetic compound libraries were screened (NSRB screening
facility, Harvard, MA, USA) for compounds that resulted in a re-
duction in fluorescence (z scores > 3.0), signifying a reduction
in T3S similar to a T3S genetic mutant (DprgH-K). This screen
yielded 89 putative T3S inhibitors that appeared to have no effect
on bacterial growth (data not shown). Of these, 57 were judged
to lack novelty or potential for drug development, 7 compounds
had an effect on bacterial growth upon further analysis (data not
shown), and 25 were further studied. Because inhibition of a va-
riety of general bacterial processes not specific to T3S would
have been positive in the HTS, including gene transcription, pro-326 Cell Host & Microbe 4, 325–336, October 16, 2008 ª2008 Elsevitein translation, sec-dependent secretion, and disulfide bond
isomerization, secondary assays were performed to define
screening positives specific for secretion.
To identify nonspecific inhibitors of transcription the expres-
sion of the flagellar regulatory gene (flhC) was measured using
a transcriptional fusion to the lacZ gene. To eliminate com-
pounds inhibiting bacterial translation, sec-dependent secretion,
or disulfide bond isomerization, alkaline phosphatase activity of
a PrgH’-‘PhoA protein fusion was measured in the presence of
the various compounds. PrgH is an essential inner membrane
component of the T3S apparatus secreted by the sec-depen-
dent pathway (Kimbrough and Miller, 2000; Kubori et al., 1998),
and alkaline phosphatase activity requires disulfide bond forma-
tion; thus, inhibition of fusion protein expression and/or its local-
ization would result in decreased alkaline phosphatase activity.
We found that while many of the identified compounds reduced
b-galactosidase activity and/or alkaline phosphatase activity,
cultures grown in the presence of 7 (TTS19, 22, 24, 26, 29, 36,
and 40) of the 25 compounds assayed had at least 60% of the
activity observed for cells grown in the absence of compound
on repeated measurement (Figure 1A). Thus, these seven
compounds lacked a strong general effect on bacterial transcrip-
tion, translation, sec-dependent secretion, and/or bacterial
growth.
These compounds could still have had a specific transcrip-
tional effect on T3S gene expression. Therefore, we measured
the effect of these compounds on transcription of a T3S operon
(the hilA operon) that encodes a transcriptional regulator for T3S
structural components and secreted substrates by again using
a transcriptional reporter fusion to lacZ. b-galactosidase activity
was measured in the presence and absence of the compounds.
We observed a greater than 85% reduction in b-galactosidase
activity for six of these compounds when cultures were grown
in the presence of compound, suggesting that they specifically
inhibited T3S transcription (Figure 1B). In contrast, activity was
similar in cultures grown in the presence or absence of one com-
pound, TTS29, suggesting that this compound, of the 92,000
screened, might specifically target the assembly or structure of
the S. typhimurium T3S system. This compound is a 2-imino-
5-arylidene thiazolidinone and we labeled it compound 1 (Fig-
ure 1C). To corroborate our initial screening data that compound
1 does not affect bacterial growth, we assayed growth over time
of S. typhimurium in growthmediumwith andwithout compound
1. No effect on bacterial growth was observed (Figure 1D).
Bacterial colony forming units were also determined and no
change was observed in the presence of compound 1 (data
not shown).
Todemonstrate specific inhibition of T3Sby this compound,we
examined the culture supernatants of S. typhimurium for T3S-se-
creted substrates when grown in the presence of compound 1
(380 mm) using Coomassie blue-stained protein gels (Figure 2A)
and western blots for the prominent T3S-secreted virulence pro-
teins,SipA,B, andC (Figure2B).Weobservedamarkeddecrease
in the amount of the T3-secreted proteins when bacterial cultures
were grown in the presence of compound 1. To clearly rule out
a complex T3S-dependent transcriptional effect, two T3S
substrates, SipA and SspH1, were expressed from the T3S-inde-
pendent lacpromoter, and their secretionwas examinedbywest-
ern blot. We found that neither of these proteins were secreteder Inc.
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(A) b-galactosidase activity from an flhC-lacZ transcriptional fusion in S. typhimurium when grown in the presence of small molecules (380 mm) identified in the
HTS screen. Activity was recorded as a percent of wild-type (WT) (blue bars), i.e., the amount of b-galactosidase activity observed when bacteria are grown in the
absence of compound. Three independent experiments were performed and the mean standard deviations are shown. Shown is alkaline phosphotase activity of
a PrgH-PhoA translational fusion in S. typhimurium when grown in the presence of small molecules (380 mm) identified in the HTS screen (red bars). Three in-
dependent experiments were performed and the mean standard deviations are shown. The dashed line (—) marks 60% of WT activity, the level used to choose
compounds for further study.
(B) b-galactosidase activity from an iagB-lacZ transcriptional fusion in S. typhimuriumwhen grown in the presence of small molecules (380 mm) with levels of flhC-
lacZ and PrgH-PhoA expression greater than 60%. As above, activity was recorded as a percent of WT. Three independent experiments were performed and the
mean standard deviations are shown.
(C) Chemical structure of TTS29, renamed compound 1.
(D) Growth curves for S. typhimurium and P. aeruginosa in LB medium with compound 1 or an equal volume of the solvent.from bacteria grown in the presence of compound 1 (data not
shown).
To support the hypothesis that compound 1 acted upon
a specific biological mechanism for inhibition of T3S, we per-
formed a dose-dependent curve with compound 1. We ana-
lyzed protein secretion by S. typhimurium in the presence of
decreasing amounts (200, 100, 40, 20, 13.3, 10, and 3.3 mm)
of compound 1. Secreted proteins were TCA precipitated andCell Hosequal amounts of sample were loaded onto an SDS-PAGE; pro-
teins were separated and western blotted with antibody to the
SipA protein (Figure 2C). Inhibition of S. typhimurium protein se-
cretion was greatest at 200 mM and diminished incrementally
with decreasing concentration of compound. To control for
sample handling and loading of the supernatant proteins, we
blotted with antibodies to FliC, the flagellar filament protein of
S. typhimurium and a predominant protein found in culturet & Microbe 4, 325–336, October 16, 2008 ª2008 Elsevier Inc. 327
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observed an increase, in FliC protein levels in the presence of
compound (Figure 2C).
Compound 1 Inhibits S. typhimurium T3S Needle
Complex Assembly or Stability without Altering Secretin
Protein Levels or Membrane Localization
The highly conserved structure of the T3S apparatus includes
a membrane-spanning complex associated with an extracellular
needle, termed the needle complex (NC) (Kubori et al., 1998;
Sekiya et al., 2001). In order to investigate the effect of com-
pound 1 on the T3S apparatus, we purified NCs from S. typhimu-
rium cells grown in the presence and absence of compound 1.
The predominant NC proteins isolated in S. typhimurium are
InvG, which forms the outer membrane ring or secretin complex,
as well as PrgH and PrgK, which form the inner membrane ring
(Kimbrough and Miller, 2000; Kubori et al., 1998; Yip et al.,
2005). Post CsCl-gradient fractions of NCs were separated by
SDS-PAGE and analyzed by western blot. An overall reduction
in NC proteins was observed when cells were grown in the pres-
ence of compound 1 (Figure 3A), suggesting that it may inhibit
formation and/or destabilize NCs.
To test whether the decrease in NCs actually resulted from
a reduction in either cellular levels or localization of NC proteins
to the bacterial membrane, we assayed cells grown in the pres-
ence and absence of compound 1 for the abundance and
localization of InvG as well as PrgH. In the presence of com-
pound 1, cellular and total membrane protein levels were unal-
tered, suggesting that localization was unchanged (Figures 3A
and 3B). Given that stable and equal amounts of InvG and
PrgH are present and localized to the membrane, these data
Figure 2. Phenotypic Effects of Compound 1 on
Type III Secretion
(A)Bacterial culturesweregrown in theabsence () orpres-
ence (+) of 380 mMof compound 1. Secreted proteins were
TCA precipitated and separated by 12.5%SDS-PAGE and
stained with Coomaisse blue. The flagellin proteins from S.
typhimurium and Y. enterocolitica are marked (*) as well as
the associated flagellar cap protein in S. typhimurium (**).
(B) Western blots of the secreted proteins SipA, B, and C
from S. typhimurium grown in the presence (+) or absence
() of compound 1.
(C) Western blots of secreted SipA protein as well as the
flagellar filament protein, FliC, in supernatants from S. ty-
phimurium grown in LB alone or with decreasing concen-
trations of compound 1.
indicate that NC formation or assembly is the
likely target of compound 1.
Compound 1 Inhibits Both Type III
Secretion Systems
in Yersinia spp
Phylogenetic analyses of conserved T3S sys-
tems indicate that these structures have
evolved into different families typified by the
Ysc system of Yersinia spp., the Inv/Spa system
of S. typhimurium and Shigella flexneri, and the
Esc system of enterohaemorrhagic E. coli
(EHEC) and the Hrp/Hrc system characteristic of plant patho-
gens such as Pseudomonas syringae (Cornelis, 2006). To exam-
ine the potential inhibitory effect of our compound on other clas-
ses of T3S systems, we analyzed the secretion profiles for the
T3S systems of Yersinia enterocolitica grown in the presence
of compound 1. The plasmid-encoded Ysc T3S system of Yersi-
nia pestis, Y. enterocolitica and Yersinia pseudotuberculosis rep-
resents a well characterized T3S system that delivers a set of
bacterial effector proteins, termed Yops (Yersinia outer proteins)
into the lumen of the target host cell resulting in inhibition of the
innate immune response (Viboud and Bliska, 2005). In contrast,
the chromosomally encoded Ysa T3S system of Y. enterocolitica
secretes a set of proteins termed Ysps (Yersinia secreted pro-
teins) (Matsumoto and Young, 2006). Although translocation of
these proteins into host cells has not been clearly demonstrated,
it is believed to contribute to the gastrointestinal stage of infec-
tion. We found that both Yop and the Ysp proteins were absent
in supernatants from Y. enterocolitca cultures grown in the pres-
ence of compound 1 (Figure 2A), indicating that these Yersinia
T3S systems were also inhibited by this compound. Similar to
S. typhimurium no difference in growth was observed for Y. en-
terocolitica grown in the presence of compound 1 (Figure S1).
Thus compound 1 appears to be a relatively broad inhibitor of
T3S systems.
Compound 1 Does Not Inhibit the Flagellar-Specific
T3S System in S. typhimurium
Virulence T3S systems are evolutionarily related to the flagellar-
specific T3S system and therefore it was plausible that com-
pound 1 inhibited flagellar secretion and mobility. Specifically,
a core of eight conserved proteins assemble the foundation of328 Cell Host & Microbe 4, 325–336, October 16, 2008 ª2008 Elsevier Inc.
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the flagellar system does not utilize the outer membrane compo-
nent, the secretin protein of the NC (Cornelis, 2006). Interest-
ingly, secretion of flagellin, the predominant substrate of this sys-
tem observable in the culture supernatant, was unaltered by the
presence of compound 1 (Figure 2A), suggesting that compound
1 does not inhibit flagellar-specific T3S. These data were corrob-
orated by western blot of the S. typhimurium supernatant pro-
teins with antibody to the flagellar filament protein, FliC
(Figure 2C). To further determine the effect of compound 1 on fla-
gellar secretion and hence function, we measured bacterial mo-
tility of S. typhimurium in motility plates containing compound 1
and compared it tomotility in plates lacking compound 1.Motility
was measured after incubation at 37C for 6 hr. We found that
motility of S. typhimurium was similar in plates with and without
compound 1 (Figure 4A). These data suggested that compound
1 may target a component of T3S systems not conserved with
the flagellar-specific T3S system.
Compound 1 Inhibits Other Secretin-Containing
Secretion Systems of Gram-Negative Bacteria
The specificity of compound 1 for other T3S systems, but not the
flagellar-specific T3S system, as well as a decrease in NC forma-
tion in the presence of compound suggested that the outer
membrane secretin protein may be the target of this small mole-
cule. If this were the case other secretion systems containing
a secretin component would possibly be inhibited, such as
T2S and T4P assembly. Bacterial T2S systems transport many
Figure 3. Phenotypic Effects of Compound 1 on Type III Secretion
Needle Complex Assembly
(A) Type III secretion needle complexes (NC) were purified fromS. typhimurium
grown in the absence () or presence (+) of 380 mM of compound 1. Proteins
were separated by SDS-PAGE and western blotted with antibodies to InvG,
PrgH, and PrgK.
(B) Total membrane fractions were isolated from S. typhimurium grown in the
absence () or presence (+) of 380 mM of compound 1. Proteins were sepa-
rated by SDS-PAGE and western blotted with antibodies to InvG and PrgH.Cell Hosubstrates from the periplasm across the outer membrane,
including a variety of mammalian toxins, as well as other pro-
teins, which degrade host cell components, such as proteins,
lipids, and sugars of the extracellular matrix (Cianciotto, 2005).
An important virulence factor of the opportunistic pathogen
Figure 4. Phenotypic Effects of Compound 1 on Alternate Secretion
Systems
(A) Motility assays of S. typhimurium and P. aeruginosa in the absence () or
presence (+) of 380 mM of compound 1. Bacteria were stabbed into motility
plates and incubated at 37C for 6 hr. The diameter of the ring was measured
for three independent biological replicates and the mean standard deviations
are shown.
(B) Elastolytic activity for 18 hr culture supernatants of P. aeruginosa grown in
the absence (WT; 1) or presence of 380 mM of compound 1 (compound 1; 3)
was determined using elastin Congo Red as a substrate. Elastase activity
was measured as a change in OD495 and can be observed as an increase in
the red color of the sample. As a negative control, elastase activity was deter-
mined for the culture supernatant of a P. aeruginosa T2S mutant (pilD; 2). As
a control for inhibition of elastase activity by the compound, compound 1
was added directly to culture supernatants fromP. aeruginosa grown in the ab-
sence of compound and assayed for elastolytic activity (WT and compound 1;
4). Pictures and the corresponding OD495 of samples are shown. Mean stan-
dard deviations are shown for three independent biological replicates.
(C) Twitching assays of P. aeruginosa (WT) in either the absence () or pres-
ence (+) of 380 mM of compound 1. Bacteria were stabbed into LB plates
with 1.0% agar and incubated for 2 days at 30C. The diameter of the twitching
ring was measured and the mean standard deviation is shown for three inde-
pendent biological replicates. A genetic mutant (pilD) defective in twitching
motility was used as a negative control and stabbed into plates with and with-
out compound 1.st & Microbe 4, 325–336, October 16, 2008 ª2008 Elsevier Inc. 329
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which is required for the ability of this organism to produce cor-
neal ulcers, skin infections and pneumonia (Wretlind and Pavlov-
skis, 1983). To determine if compound 1 inhibits the T2-depen-
dent secretion of elastase, we measured elastase in culture
supernatants from bacteria grown in the presence and absence
of compound 1 by monitoring its enzymatic activity. Elastase ac-
tivity can be measured by adding the substrate elastin conju-
gated to Congo Red to culture supernatants. Cleavage of this
substrate by elastase results in a detectable increase in absor-
bance at OD495 (McIver et al., 2004; Ohman et al., 1980). An iso-
genic strain that lacks the prepillin peptidase PilD, which is an es-
sential component of the Pseudomonas T2S system, was used
as a negative control. We observed a reduction in supernatant
elastolytic activity in culture supernatants from bacteria grown
in the presence of compound 1, similar to the pilDmutant, as in-
dicated by a decrease in the OD495, when bacteria were grown in
the presence of compound 1 (Figure 4B) as opposed to solvent
alone, suggesting an inhibition of the P. aeruginosa T2S system
by this molecule. As a control for the potential inhibition of the
compound on the enzymatic activity of elastase, compound 1
was added directly to culture supernatants from P. aeruginosa
grown in the absence of compound 1 and assayed for elastolytic
activity. We did not observe a decrease in the OD495, indicating
that compound 1 does not affect the enzymatic activity of elas-
tase. To eliminate the possibility that this effect is due to a growth
defect of P. aeruginosa in the presence of the compound, growth
curves were performed for P. aeruginosa and no difference in
growth for P. aeruginosa was observed in the presence of com-
pound 1 (Figure 1D).
Twitching motility, which is a flagellar-independent form of
bacterial motility, is mediated by T4P (Mattick, 2002). As a num-
ber of the genes required for T4P assembly are homologous to
those required for T2S, we also examined twitching motility in
P. aeruginosa in the presence and absence of compound 1 (Mat-
tick, 2002). After incubation for 2 days at 30C we measured the
diameter of the twitching ring for three independent biological
replicates. We found that the spread of bacteria from the point
of inoculation was reduced in the plates containing compound
1 (Figure 4C). In contrast, the flagellar-mediated swimming mo-
tility of P. aeruginosa was unaffected by the presence of com-
pound 1 inmotility media, further indicating that flagellar-specific
T3S systems are unaffected by compound 1 (Figure 4A).
Recently, Francisella novicida, a subspecies of F. tularensis,
the causative agent of the zoonotic disease tularemia, was dem-
onstrated to secrete a number of virulence factors through an
atypical secretion system related to T4P secretion systems (Ha-
ger et al., 2006). Francisella secretionwas shown to require a pro-
tein with amino acid similarity to secretins, and thus to further
examine the potential broad spectrum nature of 2-imino-5-aryli-
dene thiazolidinone inhibition, we used Coomaisse blue-stained
protein gels to analyze secretion of virulence proteins by F. nov-
icida when grown in the presence of compound 1 (Figure 2A).
Compound 1 inhibited secretion of the known Francisella viru-
lence proteins, and as the secretin is the only shared component
with T3S systems, these data suggest that compound 1 might
block secretion by targeting the outer membrane ring proteins
of these multiprotein systems. The growth of F. novicidawas un-
altered by the presence of the compound as determined by330 Cell Host & Microbe 4, 325–336, October 16, 2008 ª2008 ElsevOD600, 1.0385 (DMSO) versus 0.9604 (compound 1), prior to re-
moval of the supernatant.
Compound1BlockedSecretion andVirulence Functions
in Both Animal and Plant Models of Infection
Although we showed that compound 1 inhibited in vitro virulence
protein secretion, we wanted to test the impact of the inhibition
of secretion on eukaryotic cells. To determine whether com-
pound 1 blocked delivery of virulence determinants into host
cells and thus inhibited microbial virulence function, we mea-
sured cytotoxicity of bone marrow macrophages by S. typhimu-
rium in the presence of compound 1, which is T3S dependent.
The enteric pathogens Salmonella and Shigella stimulate cas-
pase-1-mediated cell death as a result of T3S-mediated translo-
cation (Miao et al., 2006). S. typhimurium cytotoxicity of macro-
phages was measured by monitoring the release of lactate
dehydrogenase, a stable cytosolic enzyme that is released
upon macrophage lysis. Bacteria were grown in the presence
or absence of compound 1 under T3S-inducing conditions and
added to macrophages at a multiplicity of infection (MOI) of 40.
Infections were allowed to proceed for 30 min or 60 min at
37C and in an atmosphere of 5% CO2. A decrease in cas-
pase-1-dependent cell death of macrophages, 40% to 0.5%
(30 min infection) or 96% to 48% (60 min infection), was ob-
served for bacteria grown in the presence of compound 1, con-
sistent with the protection of mammalian cells from bacterial
virulence in a tissue culture model of infection (Figure 5A). There-
fore compound 1 appears to block the T3-dependent cytotoxic-
ity of S. typhimurium for eukaryotic cells. In addition, compound
1was added directly tomacrophages at a concentration equal to
the sample with bacteria and compound 1. Macrophages ex-
posed to compound 1 did not lyse, indicating that compound 1
was not overtly cytotoxic to mammalian cells. Cytotoxicity of
macrophages was not observedwith the S. typhimurium T3S ge-
netic mutant (DprgH-K), as previously observed.
The bacterial plant pathogen Pseudomonas syringae pv to-
mato DC3000 requires T3S of virulence determinants to cause
disease. The hypersensitivity response (HR) elicited by P. syrin-
gae in non-host tobacco plants depends upon a functional T3S
system and is an established virulence model for this pathogen
(Huang et al., 1988). To determine the effect of compound 1 on
P. syringae HR, we coinoculated P. syringae with compound 1
or solvent (v/v) onto the leaves of Tobacco plants. The bacteria
were added at decreasing dilutions, while the concentration of
the compound remained constant. HR was measured by tissue
collapse of plants cells surrounding the point of inoculation. In
the presence of compound 1, P. syringae exhibited a reduced
ability to elicit HR in the presence of compound 1 compared
with solvent alone (Figure 5B). Tissue collapse near the point of
inoculation for compound 1 or solvent alone is tissue damage
caused during injection of compounds by a blunt-ended syringe.
Therefore this compound can block disease in an important
model of plant pathogenesis.
Structure Activity Relationships Established Features
of the Thiazolidinone Chemotype Effective
for T3S Inhibition
Thiazolidinones are a structural class associated with a variety
of biological effects, which include antibacterial, antiviral,ier Inc.
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2005). The fact that diverse and specific activities have been
demonstrated for individual compounds from this family, which
has a pluripotent common scaffold, suggests that the substitu-
ents are responsible for target selectivity. Using compounds ob-
tained both commercially and from our own synthetic work, we
performed a preliminary structure activity relationship (SAR)
study of thiazolidinone analogs. We tested, by western blot,
40 compounds structurally related to compound 1 for inhibition
of S. typhimurium SipA secretion. We found that while most of
the 40 related compounds tested had minimal inhibitory activity
on T3S (Table S1 available online), six compounds inhibited
greater than 90% of SipA secretion as determined by western
blot of supernatant proteins (Figure 6 and Table S1). These
Figure 5. Inhibition of Bacterial Virulence Phenotypes by Com-
pound 1
(A)Mouse bonemarrowmacrophages (BMMs) fromBalb/c micewere infected
with WT S. typhimurium grown in the absence (WT) or presence of 380 mM of
compound 1 (WT C1) to SPI1-inducing conditions. A T3S genetic mutant
(prgH-K) was used as a negative control. To confirm that compound 1 was
not itself cytotoxic to the macrophages, compound without bacteria (C1)
was added at a concentration equal to the experimental samples. Bacteria
were added at an MOI of 40 and cytotoxicity was assessed by LDH release
at 30 min and 60 min after infection. Assays were performed in quadruplicate
and mean standard deviations are shown.
(B) P. syringae and compound 1 were coinoculated on non-host tobacco
plants and monitored for HR. Varying concentrations of bacteria were added,
while the amount of compound or solvent (v/v) remained constant. Four inde-
pendent experiments were performed and a representative experiment is
shown. Tissue collapse near the point of inoculation for either compound 1
or solvent alone is due to tissue damage caused during injection of com-
pounds by a blunt-ended syringe.Cell Hodata allowed us to draw the following preliminary conclusions:
First, these results are consistent with requirements for the imino
nitrogen and the aryl group for inhibition of T3S (compounds 5
and 6). Second, the 5-substituent likely must be an appropriately
substituted arylidene group as reduction (compound 9), removal
(compound 8), or stripping the substituents from (compound 7)
this ring significantly diminishes activity. Finally, the amido nitro-
gen is fairly permissive (compounds 2, 3, and 4) and thus allows
for the directed evolution of increasingly active thiazolidinone an-
alogs from substitution on this nitrogen. In addition, a few of
these compounds fell out of the mainstream of the SAR and
may represent a new chemotype.
Synthesis of an Analog of Compound 1 with Increased
Solubility and Activity
Because it was possible that the poor solubility of compound 1
contributed to its requirement for a high micromolar concentra-
tion for full activity, we synthesized an analog (compound 2)
that was more hydrophilic and contained protonatable groups
that would enhance solubility. We then performed dose-depen-
dent curves. Again, secreted proteins from S. typhimurium
grown in the presence or absence of this compound were TCA
precipitated, separated by SDS-PAGE, and western blotted
with anti-SipA antibody. In contrast to compound 1, the analog
appears to inhibit most of the detectable SipA at 100 mM. Mini-
mal SipA protein was detected in the supernatant at 40 and
20 mM (Figure 7A), suggesting that compound 2 is approximately
10-fold more potent than compound 1. It was possible that the
increased activity of compound 2 was due to an acquired effect
on the growth of S. typhimuirum, and therefore we measured
growth of S. typhimurium and P. aeruginosa in the presence
and absence of compound 2. We found no effect of compound
2 on growth (Figure 7B). By measuring b-galactosidase activity
of the iagB-lacZ transcriptional fusion for bacteria grown in the
presence and absence of compound 2, we also confirmed that
compound 2, like compound 1, did not have an effect on T3
gene transcription. Similar levels of b-galactosidase activity
were observed under both conditions (Figure 7C). We also mea-
sured expression of our PrgH’-‘PhoA fusion in the presence of
compound 2. As with compound 1, we observed similar levels
of alkaline phosphatase activity when bacteria were grown in
the absence or presence of compound 2 (Figure 7C). To deter-
mine if compound 2 maintained a broad spectrum of activity,
wemeasured T2-dependent secretion of elastase into the super-
natant by P. aeruginosa. Similar to compound 1, compound 2
demonstrated an ability to inhibit elastase secretion of P. aerugi-
nosa as measured by cleavage of Congo Red conjugated to
elastin (Figure 7D), providing evidence that both compounds
are able to inhibit T3 and T2S systems. Finally, compounds 1
and 2 were found to have no effect on bacterial membrane per-
meability, as determined using 1-N-phenyl-naphthylamine and
ethidium bromide uptake assays, indicating that they were not
having a nonspecific effect on the outer membrane (data not
shown) and providing further evidence that these compounds
have a specific mechanism of action.
To determine if compound 2 was more effective at protecting
mammalian cells from bacterial virulence in a tissue culture
model of infection, we measured cytotoxicity of bone marrow
macrophages by S. typhimurium in the presence of compoundst & Microbe 4, 325–336, October 16, 2008 ª2008 Elsevier Inc. 331
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The amount of SipA protein in culture supernatants was determined by western blot for three independent replicates and standard deviations are shown.
Compounds were tested at a final concentration of 380 mm.2. Bacteria were grown in the presence or absence of
compound 2 under T3S-inducing conditions and added to mac-
rophages at an MOI of 40. Infections were allowed to proceed
for 60 min at 37C and in an atmosphere of 5% CO2. A de-
crease in caspase-1-dependent cell death of macrophages,
from 68% to 9%, was observed for bacteria grown in the pres-
ence of compound 2 (100 mm) (Figure 7E). This is greater than
the protection observed with compound 1 (380 mm) at 60 min,
95% to 48%, suggesting that compound 2 is more effective
than compound 1 at protecting mammalian cells from bacterial
virulence. Again, compound was added directly to macro-
phages at a concentration equal to the sample with bacteria
and compound. Macrophages exposed to compound 2 ex-
hibited minimal LDH release, suggesting that compound 2 is
also not cytotoxic to mammalian cells. These data indicate
that compounds of higher activity can be generated without332 Cell Host & Microbe 4, 325–336, October 16, 2008 ª2008 Elsevisacrificing features important for potential bioavailability as
well as a broad spectrum of activity.
DISCUSSION
The increase in knowledge of bacterial virulence properties has
led investigators to consider them as targets for the develop-
ment of therapeutic agents (Marra, 2006). Such agents would
possibly block disease without killing the pathogen or commen-
sal bacteria. In this study, we designed and implemented a trac-
table high-throughput screen (HTS) that identified small-mole-
cule inhibitors of Gram-negative bacterial virulence-associated
secretion systems, required for the pathogenesis of numerous
global infectious agents. We identified a 2-imino-5-arylidene
thiazolidinone that inhibits bacterial secretion systems in
a wide array of animal and plant pathogens without alteringer Inc.
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Inhibitor of Bacterial Virulence Protein SecretionFigure 7. Characterization of Secretion Inhibition by Compound 2
(A) Western blots of secreted SipA protein as well as the flagellar filament protein, FliC, in supernatants from S. typhimurium grown in LB alone or with decreasing
concentrations (1, 200 mm; 2, 100 mm; 3, 40 mm; 4, 13.3 mm; 5, 10 mm; and 6, 3.3 mm) of compound 2.
(B) Growth curves for S. typhimurium and P. aeruginosa in LB medium with compound 2 or an equal volume of solvent.
(C) b-galactosidase activity (blue bar) from an iagB-lacZ transcriptional fusion in S. typhimurium or the amount of alkaline phosphotase activity (red bar) observed
fromaPrgH’-‘PhoA translational fusion inS. typhimuriumwhengrown in thepresenceof compound2 (100mm). Enzymatic activitywas recordedasapercentofWT,
i.e., the amount of activity observed in the absence of compound. Three independent experiments were performed and the mean standard deviations are shown.
(D) Elastolytic activity for 18 hr culture supernatants of P. aeruginosa grown in the absence (1) or presence of compound 2 at varying concentrations (3, 4, and 5)
was determined using elastin Congo Red as a substrate. Elastase activity was measured as a change in OD495 and can be observed as an increase in the red
color of the sample. As a negative control, elastase activity was determined for the culture supernatant of a P. aeruginosa T2S mutant (pilD; 2). Pictures and the
corresponding OD495 of samples are shown.
(E) Mouse BMMs were infected with WT S. typhimurium grown in the absence (WT) or presence of 100 mm of compound 2 (WT C2), a T3S mutant (prgH-K), or
compound 2 without bacteria (C2). Bacteria were added at an MOI of 40 and cytotoxicity was assessed by LDH release at 60 min. Assays were performed in
quadruplicate and mean standard deviations are shown.bacterial growth. A variety of genetic and biochemical studies
suggest that compounds 1 and 2 act by inhibiting the conserved
components of secretion systems not utilized by the flagellar
secretion system. The active compound was further demon-
strated to inhibit T3S-dependent S. typhimurium cytotoxicity
for macrophages as well as the pathology of the plant pathogen,
P. syringae, on Tobacco. Finally, by testing for activity of a broad
array of purchased and synthesized analogs, a defined secretion
inhibitor chemotype was determined and an analog with in-
creased solubility and activity was identified.Cell HosThiazolidinones appear in a diverse array of drug discovery
programs and substituted thiazolidinones are under investiga-
tion as anticancer antagonists, antischistosomal agents, and
general antifungal/antimicrobial agents (Dayam et al., 2006;
Khare et al., 1995; Manhi and Mahoud, 2007; Merja et al.,
2004; Qin et al., 2006; Rajanarendar et al., 2004). Moreover,
many thiazolidinones are highly potent and target specific, sug-
gesting that the substituents impart a high degree of selectivity to
the common core of these small molecules. Our initial SAR
studies suggest that the 2-imino-5-arylidene thiazolidinonet & Microbe 4, 325–336, October 16, 2008 ª2008 Elsevier Inc. 333
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imino N-2, amido N-3, and 5-arylidene groups. This sensitivity
supports the hypothesis that specific molecular interactions be-
tween the small molecule ligand and the cognate protein(s) are
required for inhibiting bacterial secretion. In addition, we were
able to rationally design and synthesize compound 2 (unpub-
lished data), an analog of compound 1 that demonstrated in-
creased activity and enhanced solubility. The reappearance of
the thiazolidinone motif in a wide variety of research studies indi-
cates that compounds developed from this scaffold may have
the potential to be developed into therapeutic agents with low
toxicity and the required pharmacokinetic and bioavailability
properties to be useful clinically.
As T2 and T3 bacterial secretion systems have a single shared
protein component, our data suggest that compound 1 is medi-
ating its broad spectrum of activity by targeting this protein—the
secretin (Yip and Strynadka, 2006). Secretins are outer mem-
brane-spanning proteins that are synthesized in the bacterial cy-
toplasm and subsequently exported across the inner membrane
by the sec-dependent pathway. These proteins have a similar
overall structure, i.e., secretin proteins have two major domains,
which are approximately equal in length. The C-terminal domain
is well conserved and believed to anchor the protein in the mem-
brane by 10–14 transmembrane amphipathic b strains charac-
teristic of other outer membrane proteins (Guilvout et al.,
1999). In contrast, the N-terminal domain ismuch less conserved
and believed to facilitate recognition of substrates and confer se-
cretion specificity. These proteins associate into a highly stable
oligomeric complex of 12–14 subunits in the bacterial outer
membrane, which functions as an export channel for substrate
secretion across this barrier, by both T2 and T3 bacterial secre-
tion systems (Bitter, 2003). Here we present data that the amount
of assembled NCs, the multiprotein secretin-containing trans-
membrane complex of the T3S system of S. typhimuirum, in
the bacterial membrane is reduced when bacterial cultures are
grown in the presence of compound 1, but the amount of secre-
tin protein, InvG, in the bacterial membrane is unaltered. These
data suggest that compound 1 may mediate its effect by target-
ing the seretin protein, but the molecular mechanism of action of
these compounds needs to be further examined.
Since the discovery of the secretion of virulence factors, inves-
tigators studying bacterial pathogenesis have investigated the
feasibility of developing broad spectrum antimicrobials with the
ability to specifically inhibit toxin secretion. The diversity of deliv-
ery systems for bacterial toxins, as well as the vast homo- and
heterooligomeric architecture of these structures, has made
the practicality of this concept a daunting endeavor. It was im-
possible to predict that 2-imino-5-arylidene thiazolidinones
could be developed that would have broad activity, but in this
work a combination of an HTS screen, secondary assays, and
hit to lead chemistry identified these small molecules as potential
broad spectrum antivirulence agents for Gram-negative bacteria
by inhibiting a diversity of bacterial secretion systems.
EXPERIMENTAL PROCEDURES
Strain Construction and Bacterial Growth Conditions
Salmonella, Yersinia, and Pseudomonas strains were grown in Luria-Bertani
(LB) medium, while Francisella was grown in Tryptic Soy Broth supplemented334 Cell Host & Microbe 4, 325–336, October 16, 2008 ª2008 Elseviwith 0.1% cysteine. Motility media were made as previously described (Maloy
et al., 1996; Semmler et al., 1999). For cytotoxicity assays, Salmonella strains
were grown overnight and diluted 1:40 (v/v) and were grown for 3 hr to induce
T3S gene expression. For all experiments, unless indicated otherwise, com-
pound 1 was used at a concentration of 380 mM and compound 2 was used
at a concentration of 100 mm. Corresponding cultures were grown in the pres-
ence of an equal concentration of the solvent (v/v) without compound. Bacte-
rial strains were constructed using P22HT int transduction and the l-RED
system (Datsenko andWanner, 2000; Maloy et al., 1996). Strains used in these
studies are listed in the Supplemental Data (Table S2).
Screening
See Supplemental Data.
Enzymatic Assays
b-galactosidase and alkaline phosphatase assays were performed following
protocols previously described (Maloy et al., 1996). Elastase assays were per-
formed as described (McIver et al., 2004; Ohman et al., 1980).
Compounds
Compoundswere purchased fromChemDiv (compounds TTSS4, TTSS11-22,
TTSS24), Biomol (compounds TTSS26, TTSS28-29), Maybridge (compounds
TTSS36, TTSS39-40, and TTSS42-43), IF Labs (TTSS44-45), and Bionet
(TTSS47). Compounds were checked for purity by HPLC and found to be
>90% pure. Compounds for the SAR were purchased from Akos, Aurora,
Chembridge, ChemDiv, Interchim AnaLogix, Princeton Bio, and Ryan as well
as synthesized at the University of Washington, Seattle, Washington.
Protein Chemistry
Secreted proteins were prepared as previously described for S. typhimurium
(Kimbrough and Miller, 2000), Y. enterocolitica (Young and Young, 2002),
and F. novicida (Hager et al., 2006). Cellular samples were derived from lysed
whole cells, while total membrane fractions resulted from ultracentrifugation of
this lysate to pellet themembrane. T3S NCswere isolated from S. typhimurium
as previously described (Kimbrough andMiller, 2000). SDS-PAGE andwestern
blot techniques were performed as described (Pegues et al., 1995).
Virulence Studies
For cytotoxicity assays, bone marrow macrophages (BMMs) were plated and
infected the following day. S. typhimuriumwas added at a MOI of 40, diluted in
100 ml media, and added to BMMs. Infections were allowed to proceed for 30
or 60 min at 37C in an atmosphere of 5% CO2. Lactate dehydrogenase (LDH)
activity was measured on 50 ml of supernatant using the CytoTox 96 assay
(Promega). Each sample was done in quadruplicate and the average values
are shown. For the HR assays, P. syringae DC3000 was resuspended from
plates in 100 mM sucrose and 10 mMMgCl2 to a final OD600 of 0.3 and diluted
1:20, 1:40, 1:60, and 1:80. Bacteria were incubated with DMSO or compound
for 30 min at room temperature (RT) in the dark. Samples were injected into
Nicotiana benthamiana plants and pictures taken 36 hr post-inoculation.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, one fig-
ure, and one table and can be found with this article online at http://www.
cellhostandmicrobe.com/supplemental/S1931-3128(08)00257-6.
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